1.
Bone Marrow Transplant
; 58(1): 109-111, 2023 01.
Artículo
en Inglés
| MEDLINE
| ID: mdl-36261706
2.
Transplant Cell Ther
; 27(1): 96-97, 2021 01.
Artículo
en Inglés
| MEDLINE
| ID: mdl-33049396
3.
Cureus
; 12(10): e10937, 2020 Oct 14.
Artículo
en Inglés
| MEDLINE
| ID: mdl-33062462
RESUMEN
Chimeric antigen receptor T-lymphocytes (CAR T) targeting the CD19 surface antigen have achieved a breakthrough in the treatment of multiply relapsed and refractory bone marrow (BM) disease in childhood B-cell precursor acute lymphoblastic leukaemia (B-ALL). The ability of CAR T therapy to treat extramedullary (EM) disease is less proven. However, early reports suggest trafficking of CART-cells to the central nervous system (CNS) as well as other EM sites. We describe a case of isolated intraocular relapse of pediatric B-ALL following CAR T-cell therapy, which had successfully controlled multiply relapsed BM and CNS disease. CAR T-cells may not be able to traffic into the eye, making it a "sanctuary" site during therapy.
4.
Pediatr Hematol Oncol
; 37(5): 353-354, 2020 08.
Artículo
en Inglés
| MEDLINE
| ID: mdl-32469622